{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Hormone-dependent",
    "query": {
      "condition": "Neoplasms, Hormone-dependent"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Hormone-dependent&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T04:08:18.559Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05351892",
      "title": "A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men",
        "Hot Flashes",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Elinzanetant (BAY3427080)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 18,
      "start_date": "2022-05-04",
      "completion_date": "2022-06-20",
      "has_results": false,
      "last_update_posted_date": "2022-07-19",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05351892"
    },
    {
      "nct_id": "NCT02420652",
      "title": "Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Prostate Carcinoma",
        "Stage I Prostate Cancer",
        "Stage IIA Prostate Cancer",
        "Stage IIB Prostate Cancer",
        "Stage III Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Metformin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2015-06-23",
      "completion_date": "2019-12-01",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02420652"
    },
    {
      "nct_id": "NCT05262400",
      "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PF-07220060 + PF-07104091 combination dose escalation",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + PF-07220060 + letrozole dose expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2022-03-14",
      "completion_date": "2026-08-23",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05262400"
    },
    {
      "nct_id": "NCT00726596",
      "title": "Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 64,
      "start_date": "2008-08",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2022-06-16",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 5,
      "location_summary": "Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more",
      "locations": [
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Summit",
          "state": "New Jersey"
        },
        {
          "city": "Voorhees Township",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00726596"
    },
    {
      "nct_id": "NCT01220973",
      "title": "Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "atorvastatin calcium",
          "type": "DRUG"
        },
        {
          "name": "celecoxib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2009-02",
      "completion_date": "2014-11-18",
      "has_results": true,
      "last_update_posted_date": "2018-06-08",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 4,
      "location_summary": "Detroit, Michigan • Camden, New Jersey • Hamilton, New Jersey + 1 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        },
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01220973"
    },
    {
      "nct_id": "NCT00044291",
      "title": "Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Neoplasms, Hormone-dependent"
      ],
      "interventions": [
        {
          "name": "atamestane",
          "type": "DRUG"
        },
        {
          "name": "toremifene",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "aromatase inhibition",
          "type": "DRUG"
        },
        {
          "name": "hormone therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "endocrine therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "antiestrogen therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Intarcia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 865,
      "start_date": "2002-06",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2015-07-31",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 17,
      "location_summary": "Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more",
      "locations": [
        {
          "city": "Lake Havasu City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami Shores",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044291"
    },
    {
      "nct_id": "NCT05307328",
      "title": "SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cushing's Syndrome I",
        "Cushing Disease Due to Increased ACTH Secretion",
        "Cortisol Excess",
        "Cortisol; Hypersecretion",
        "Cortisol Overproduction",
        "Ectopic ACTH Secretion"
      ],
      "interventions": [
        {
          "name": "SPI-62",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sparrow Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2022-09-01",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05307328"
    },
    {
      "nct_id": "NCT00267553",
      "title": "Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Neoplasms, Hormone-Dependent"
      ],
      "interventions": [
        {
          "name": "Atamestane",
          "type": "DRUG"
        },
        {
          "name": "toremifene",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intarcia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2005-11",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2007-09-10",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 6,
      "location_summary": "Greenbrae, California • Saint Joseph, Michigan • Kansas City, Missouri + 3 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Saint Joseph",
          "state": "Michigan"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00267553"
    },
    {
      "nct_id": "NCT02632045",
      "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "LEE-011",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melissa K Accordino",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2016-03",
      "completion_date": "2022-01-04",
      "has_results": true,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02632045"
    },
    {
      "nct_id": "NCT00097344",
      "title": "The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Neoplasms, Hormone-Dependent"
      ],
      "interventions": [
        {
          "name": "Atamestane",
          "type": "DRUG"
        },
        {
          "name": "Toremifene",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Aromatase inhibition",
          "type": "DRUG"
        },
        {
          "name": "Estrogen receptor blocker",
          "type": "DRUG"
        },
        {
          "name": "Hormone therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Endocrine therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Antiestrogen therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Intarcia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 842,
      "start_date": "2004-12",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2007-08-23",
      "last_synced_at": "2026-09-12T04:08:18.559Z",
      "location_count": 49,
      "location_summary": "Mobile, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 46 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097344"
    }
  ]
}